Navigation Links
Childers, Schlueter & Smith, LLC Set for Reglan/metoclopramide Jury Trial Involving Woman's Development of Tardive Dyskinesia
Date:7/19/2010

ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010.  The case is Susan Swicegood v. Pliva et. al. in the United States District Court, Northern District of Georgia, Atlanta Division.

The lawsuit alleges that the drug makers and marketers of Reglan/metoclopramide failed to adequately warn physicians of the long-term dangers associated with taking the drug, specifically, the neurological disorder tardive dyskinesia.

Reglan and its generic equivalent, metoclopramide, are used to treat several types of stomach disorders including nausea and acid reflux. The complaint alleges that Ms. Swicegood's doctor prescribed 10mg Reglan to be taken four times daily. Ms. Swicegood took the generic form of the drug and developed a permanent movement disorder called tardive dyskinesia as a result - a disorder of the nerves in which involuntary, repetitive movements develop in the lower portion of the face and in limbs.

Previous and Pending Reglan lawsuits, which now total over 150 filed, prompted the FDA to change requirements in the labeling of the drug in February 2009 to account for the increased risk of developing tardive dyskinesia from Reglan/metoclopramide use. New rules included a "Black Box" warning about the potential risk of tardive dyskinesia from long-term use. However, the suit alleges that the Physician's Desk Reference used by Ms. Swicegood's doctor was not updated with the new warnings as required by law.  As a result, neither the patient nor her doctor under
'/>"/>

SOURCE Childers, Schlueter & Smith, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care ... improving outcomes and the cost of healthcare delivery ... AEX: PHIA) today announced its presence at  ESC Congress 2015 , ... Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect ...
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Ontario, July 18, 2011 CardioGenics Holdings Inc. (CGNH.OB) ... available for on-demand viewing at the RetailInvestorConferences website. ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About CardioGenics ...
... July 18, 2011 Coronado Biosciences, Inc. (the "Company"), ... immunotherapy agents for the treatment of autoimmune diseases and ... on Form 10 with the Securities and Exchange Commission ... the purpose of becoming a reporting company.  The filing ...
Cached Medicine Technology:CardioGenics Holdings Inc. Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Coronado Biosciences Files to Become a Public Reporting Company 2
(Date:8/29/2015)... Raleigh, NC (PRWEB) , ... August 29, 2015 ... ... about how mesothelioma develops, may extend and improve the lives of patients, according ... its website. Click here to read the full article. , The ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... A study in the New England Journal of Medicine ... of lung cancer are responding positively to a treatment that ... shows 57 percent of patients with ALK-positive advanced non-small cell ... crizotinib, an investigational anaplastic lymphoma kinase (ALK) inhibitor. In some ...
... Beta cells, which make insulin in the human body, do ... may be closer to better treating diabetes. Type 1 ... auto-immunity while type 2 is due to a relative insufficiency ... remained an open issue, and is critically important for designing ...
... -- The rate of new cases of end-stage kidney disease ... between 1996 and 2007, a new study has found. ... end-stage renal disease (ESRD), that was linked to diabetes declined ... time. The declining rates occurred in all regions and in ...
... the immune system and nervous system turn Neuroimmunology into ... Between October 26th and 30th takes place in Sitges ... the International Society of Neuroimmunology. This event highlights the ... to new technologies, but also highlights the long road ...
... Commonwealth University Massey Cancer Center recently was awarded ... Tobacco Indemnification and Community Revitalization Commission (Tobacco Commission) ... involvement and to grow its state-of-the-art clinical research ... is already in place in communities across Virginia, ...
... (HealthDay News) -- Two-thirds of preschoolers in the United ... hours per day of screen time from television, computers, ... of Pediatrics, a new study has found. Researchers ... Washington looked at the daily screen time of nearly ...
Cached Medicine News:Health News:People with specific kind of lung cancer respond to new targeted treatment 2Health News:People with specific kind of lung cancer respond to new targeted treatment 3Health News:Insulin-creating cell research may lead to better diabetes treatment 2Health News:Drop Seen in Rate of End-Stage Kidney Disease in Diabetics 2Health News:Multiple sclerosis will become a controlled disease like AIDS 2Health News:VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission 2Health News:U.S. Preschoolers Getting Too Much Screen Time: Study 2
... A stethoscope adapter for users of ... acrylic shell type., ,Impressions of ... ,Westone custom products for the ear ... of hearing healthcare providers. These providers ...
Advanced architecture. Small, lightweight and compact. Easy to use....
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
Medicine Products: